Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pola-ZR-Glo in Older Treatment-naive Patients With Large B-cell Lymphoma
NCT07514169Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Mar 2026
- Primary completion
- Dec 2028
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of polatuzumab vedotin, zanubrutinib, lenalidomide, glofitamab in diffuse large B-cell lymphoma (DLBCL), sponsored by Ruijin Hospital. Started Mar 2026; status: recruiting.
02
Drugs
polatuzumab vedotinzanubrutiniblenalidomideglofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07514169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07514169.